Incyte nears up to $2B deal for blood-disorder biotech Star — FT

• Incyte will pay $1.25 billion upfront in cash to Star's venture capital backers
• An additional $750 million is contingent on achieving certain performance milestones
• The deal targets Star Therapeutics, a biotech focused on developing blood disorder treatments

Summary: Incyte Nears $2B Acquisition of Star Therapeutics

Key Transaction Details:

U.S. biotech company Incyte Pharma is close to finalizing an acquisition of Star Therapeutics, a blood disorder drug developer, in a deal valued at up to $2 billion, according to Financial Times sources. The transaction structure includes $1.25 billion in upfront cash payments to Star's venture capital investors, plus an additional $750 million contingent on achieving specific performance milestones.

Companies and Sector:

• Acquirer: Incyte Pharma (U.S. biotechnology company)
• Target: Star Therapeutics (blood disorder drug developer)
• Sector: Biotechnology/biopharmaceuticals, specifically focused on hematology

Financial Breakdown:

• Total deal value: Up to $2 billion
• Upfront cash payment: $1.25 billion
• Milestone-based payments: $750 million
• Payment structure: 62.5% upfront, 37.5% contingent

Market Implications:

This acquisition signals continued consolidation in the biotechnology sector, particularly in the blood disorder therapeutic space. The significant upfront payment demonstrates Incyte's commitment to expanding its hematology portfolio. The milestone-based structure suggests performance risks remain, with nearly 40% of the deal value tied to future achievements. For Star's VC backers, this represents a major liquidity event.

Status:

The deal is reportedly nearing completion as of June 7, though Reuters could not independently verify the report at publication time. No official announcements from either company have been confirmed.

The acquisition would strengthen Incyte's position in blood disorder treatments, a strategic area for specialized biotechnology firms.